Quipt Home Medical (NASDAQ:QIPT) Price Target Lowered to $9.50 at Stifel Nicolaus

Quipt Home Medical (NASDAQ:QIPT - Get Free Report) had its price target decreased by investment analysts at Stifel Nicolaus from $10.50 to $9.50 in a research report issued on Friday, BayStreet.CA reports. The firm presently has a "buy" rating on the stock. Stifel Nicolaus' target price suggests a potential upside of 201.59% from the company's previous close.

A number of other equities analysts also recently commented on the company. Canaccord Genuity Group lowered their price objective on Quipt Home Medical from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Friday. Raymond James downgraded Quipt Home Medical from a "market perform" rating to an "underperform" rating and lowered their price target for the company from $10.00 to $2.50 in a report on Friday.

Quipt Home Medical Stock Down 7.4 %

Shares of Quipt Home Medical stock traded down $0.25 on Friday, reaching $3.15. 932,978 shares of the company were exchanged, compared to its average volume of 162,021. Quipt Home Medical has a 1-year low of $3.10 and a 1-year high of $6.13. The company has a market cap of $134.10 million, a P/E ratio of -31.50 and a beta of 0.68. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.13 and a quick ratio of 0.79. The stock's 50 day moving average price is $4.00 and its 200-day moving average price is $4.46.

Quipt Home Medical (NASDAQ:QIPT - Get Free Report) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. Quipt Home Medical had a negative return on equity of 3.89% and a negative net margin of 1.71%. The business had revenue of $65.36 million during the quarter, compared to the consensus estimate of $63.43 million. As a group, equities analysts forecast that Quipt Home Medical will post 0.04 EPS for the current year.

Institutional Investors Weigh In On Quipt Home Medical

Several large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Quipt Home Medical by 25.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,829 shares of the company's stock valued at $57,000 after acquiring an additional 2,640 shares during the period. Connors Investor Services Inc. boosted its holdings in shares of Quipt Home Medical by 26.7% in the first quarter. Connors Investor Services Inc. now owns 52,208 shares of the company's stock valued at $228,000 after acquiring an additional 11,000 shares during the period. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Quipt Home Medical in the first quarter valued at approximately $50,000. Russell Investments Group Ltd. boosted its holdings in shares of Quipt Home Medical by 2.4% in the first quarter. Russell Investments Group Ltd. now owns 511,348 shares of the company's stock valued at $2,235,000 after acquiring an additional 12,070 shares during the period. Finally, Claret Asset Management Corp boosted its holdings in shares of Quipt Home Medical by 4.2% in the first quarter. Claret Asset Management Corp now owns 4,490,857 shares of the company's stock valued at $19,636,000 after acquiring an additional 180,539 shares during the period. 42.85% of the stock is owned by institutional investors and hedge funds.

About Quipt Home Medical

Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment.